Skip to main content

Wound Closure

0
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
"STRATAFIX™ Symmetric" Knotless TissueN/A
STRATAFIX PDS and Monocryl suturePHASE_41 trial
Active Trials
NCT07225101Recruiting160Est. Dec 2026
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
"STRATAFIX™ Symmetric" Knotless TissueN/A1 trial
Active Trials
NCT03305887Completed184Est. May 2018
Imbed Biosciences
Imbed BiosciencesWI - Middleton
1 program
Microlyte DualGuardN/A1 trial
Active Trials
NCT07695688Not Yet Recruiting53Est. Aug 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Johnson & JohnsonSTRATAFIX PDS and Monocryl suture
Imbed BiosciencesMicrolyte DualGuard
UNION therapeutics"STRATAFIX™ Symmetric" Knotless Tissue

Clinical Trials (3)

Total enrollment: 397 patients across 3 trials

NCT07225101Johnson & JohnsonSTRATAFIX PDS and Monocryl suture

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Start: Nov 2025Est. completion: Dec 2026160 patients
Phase 4Recruiting
NCT07695688Imbed BiosciencesMicrolyte DualGuard

Safety Study of Microlyte DualGuard

Start: Aug 2026Est. completion: Aug 202753 patients
N/ANot Yet Recruiting
NCT03305887UNION therapeutics"STRATAFIX™ Symmetric" Knotless Tissue

Symmetric on Total Knee Arthroplasty (TKA)

Start: Jun 2017Est. completion: May 2018184 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 397 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.